Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of SM3 pre-treatment to reduce anti-alemtuzumab antibodies in early relapsing-remitting multiple sclerosis
2005-002305-23Phase 2Completed
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Jan 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of alemtuzumab in multiple sclerosis (MS) (2 arms), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoint: Incidence of anti-alemtuzumab antibodies. Started Jan 2008; status: completed.
02
Drugs
alemtuzumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2005-002305-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002305-23.